The hormone therapy market size has grown strongly in recent years. It will grow from $19.7 billion in 2024 to $21.1 billion in 2025 at a compound annual growth rate (CAGR) of 7.1%. The growth in the historic period can be attributed to medical advancements, women's health revolution, increased awareness and education, clinical research and development, shifting healthcare practices.
The hormone therapy market size is expected to see strong growth in the next few years. It will grow to $28.46 billion in 2029 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to personalized medicine approach, aging population dynamics, shift in women's health approaches, focus on wellness and longevity, regulatory adaptations. Major trends in the forecast period include regulatory changes and guidelines, changing lifestyles and stress, research and development, expanding awareness and education.
The growth of the hormone therapy market is significantly fueled by a surge in the incidences of hormone imbalance disorders. Hormone imbalance occurs when the body produces an excess or insufficient amount of a hormone, leading to various disorders such as hypothyroidism, hypogonadism, and growth hormone deficiency. Hormone therapies, including estrogen replacement, testosterone replacement, and insulin therapy, are employed to address these disorders. A 2022 report by London Medical Laboratory revealed an anticipated 19% increase in significant hormone imbalances compared to two years prior. Consequently, the rising prevalence of hormone imbalance disorders is expected to propel the hormone therapy market.
The growing number of elderly individuals is anticipated to drive the expansion of the hormone therapy market in the coming years. Elderly individuals are those in the later stages of life, often associated with the older population or seniors. Hormone therapy for the elderly, especially regarding age-related health issues, aims to rectify hormonal imbalances and address specific conditions linked to aging. For example, in July 2024, the UK Parliament, a UK-based governmental organization, projected that the population of the UK would reach 70 million by 2026. Furthermore, the population is aging, with 19% of individuals aged 65 or older in 2022, a figure expected to increase to 27% by 2072. Thus, the rising number of elderly individuals is propelling the growth of the hormone therapy market.
Leading companies in the hormone therapy market are focusing on innovative solutions, such as direct-to-consumer telehealth models, to improve accessibility and convenience for patients. The direct-to-consumer telehealth model for hormone therapy is a healthcare system that enables patients to access hormone therapy remotely, without needing traditional in-person consultations. For example, in September 2023, LifeMD, a US-based telehealth company, partnered with ASCEND Therapeutics, a US-based pharmaceutical company, to launch an integrated direct-to-consumer telehealth model for hormone therapy, focusing on EstroGel (estradiol gel) to treat menopausal symptoms. This collaboration allows patients to utilize LifeMD's telehealth services directly through the EstroGel website, where they can consult with licensed healthcare providers who can prescribe the medication and arrange home delivery. By simplifying access and addressing barriers such as long wait times, this initiative aims to improve health outcomes for women seeking menopause treatment.
Companies in the hormone therapy market are adopting strategic partnerships to commercialize hormone therapy in North Africa and the Middle East. Strategic partnerships involve companies leveraging their strengths and resources to achieve shared goals. For instance, in October 2023, Cosmo Pharmaceuticals N.V., an Ireland-based pharmaceutical manufacturer of hormonal drugs, announced a strategic agreement with Hikma Pharmaceuticals PLC. Under this deal, Hikma will receive the exclusive rights to register and market Winlevi in 17 countries across the Middle East and North Africa (MENA) region from Cassiopea, a subsidiary of Cosmo. In return, Cassiopea will receive an initial payment of USD 750,000, along with future regulatory and commercial milestone payments. Cassiopea will remain the sole supplier of the product, with pricing based on net sales. Hikma Pharmaceuticals PLC is a UK-based pharmaceutical company.
In July 2022, Grünenthal Group, a German pharmaceutical company, acquired the testosterone treatment Nebido from Bayer AG for approximately $547.4 million. This strategic move is part of Grünenthal's ongoing acquisition strategy, which includes global rights to Qutenza, rights to ex-Japanese company Zomig, global rights to ex-US company Vimovo, and European rights to Crestor and Nexium. Bayer AG, a German pharmaceutical company specializing in hormone therapy and treatments, was the seller in this acquisition.
Major companies operating in the hormone therapy market include Abbott Laboratories, Bayer AG, Eli Lilly and Company, F. Hoffmann-La Roche, Merck KGaA, Mylan NV, Novartis AG, Novo Nordisk AS, Pfizer Inc., Abbvie Inc., Teva Pharmaceutical Industries Ltd., Perrigo Company Plc., Cipla Inc., Lupin Limited, Sun Pharmaceuticals Industries Ltd., Hikma Pharmaceuticals PLC., Johnsons & Johnsons Services Inc., Boehringer Ingelheim International GmbH, Sanofi S.A., AstraZeneca plc, TherapeuticsMD Inc., Amgen Inc., Genentech Inc., Dr. Reddy's Laboratories Ltd, Allergan PLC, GlaxoSmithKline plc, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Daiichi Sankyo Company Limited.
North America was the largest region in the hormone therapy market in 2024. The regions covered in the hormone therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hormone therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Hormone therapy is a form of treatment aimed at modifying, suppressing, or increasing specific hormones within the body. This therapeutic approach is employed to address hormonal imbalances, such as hypothyroidism and other related conditions.
Key categories of hormone therapy include estrogen hormone replacement, growth hormone replacement, thyroid hormone replacement, and testosterone replacement. Estrogen hormone replacement therapy involves the administration of estrogen to elevate the body's estrogen levels. This treatment is delivered through various routes, including oral and parenteral methods. It finds application in conditions such as menopause, hypothyroidism, and growth hormone deficiency. Distribution channels for hormone therapy encompass hospital pharmacies, retail pharmacies, and online pharmacies.
The hormone therapy market research report is one of a series of new reports that provides hormone therapy market statistics, including hormone therapy industry global market size, regional shares, competitors with a hormone therapy market share, detailed hormone therapy market segments, market trends and opportunities, and any further data you may need to thrive in the hormone therapy industry. This hormone therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The hormone therapy market includes revenues earned by entities by providing hormone therapies such as insulin therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The hormone therapy market size is expected to see strong growth in the next few years. It will grow to $28.46 billion in 2029 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to personalized medicine approach, aging population dynamics, shift in women's health approaches, focus on wellness and longevity, regulatory adaptations. Major trends in the forecast period include regulatory changes and guidelines, changing lifestyles and stress, research and development, expanding awareness and education.
The growth of the hormone therapy market is significantly fueled by a surge in the incidences of hormone imbalance disorders. Hormone imbalance occurs when the body produces an excess or insufficient amount of a hormone, leading to various disorders such as hypothyroidism, hypogonadism, and growth hormone deficiency. Hormone therapies, including estrogen replacement, testosterone replacement, and insulin therapy, are employed to address these disorders. A 2022 report by London Medical Laboratory revealed an anticipated 19% increase in significant hormone imbalances compared to two years prior. Consequently, the rising prevalence of hormone imbalance disorders is expected to propel the hormone therapy market.
The growing number of elderly individuals is anticipated to drive the expansion of the hormone therapy market in the coming years. Elderly individuals are those in the later stages of life, often associated with the older population or seniors. Hormone therapy for the elderly, especially regarding age-related health issues, aims to rectify hormonal imbalances and address specific conditions linked to aging. For example, in July 2024, the UK Parliament, a UK-based governmental organization, projected that the population of the UK would reach 70 million by 2026. Furthermore, the population is aging, with 19% of individuals aged 65 or older in 2022, a figure expected to increase to 27% by 2072. Thus, the rising number of elderly individuals is propelling the growth of the hormone therapy market.
Leading companies in the hormone therapy market are focusing on innovative solutions, such as direct-to-consumer telehealth models, to improve accessibility and convenience for patients. The direct-to-consumer telehealth model for hormone therapy is a healthcare system that enables patients to access hormone therapy remotely, without needing traditional in-person consultations. For example, in September 2023, LifeMD, a US-based telehealth company, partnered with ASCEND Therapeutics, a US-based pharmaceutical company, to launch an integrated direct-to-consumer telehealth model for hormone therapy, focusing on EstroGel (estradiol gel) to treat menopausal symptoms. This collaboration allows patients to utilize LifeMD's telehealth services directly through the EstroGel website, where they can consult with licensed healthcare providers who can prescribe the medication and arrange home delivery. By simplifying access and addressing barriers such as long wait times, this initiative aims to improve health outcomes for women seeking menopause treatment.
Companies in the hormone therapy market are adopting strategic partnerships to commercialize hormone therapy in North Africa and the Middle East. Strategic partnerships involve companies leveraging their strengths and resources to achieve shared goals. For instance, in October 2023, Cosmo Pharmaceuticals N.V., an Ireland-based pharmaceutical manufacturer of hormonal drugs, announced a strategic agreement with Hikma Pharmaceuticals PLC. Under this deal, Hikma will receive the exclusive rights to register and market Winlevi in 17 countries across the Middle East and North Africa (MENA) region from Cassiopea, a subsidiary of Cosmo. In return, Cassiopea will receive an initial payment of USD 750,000, along with future regulatory and commercial milestone payments. Cassiopea will remain the sole supplier of the product, with pricing based on net sales. Hikma Pharmaceuticals PLC is a UK-based pharmaceutical company.
In July 2022, Grünenthal Group, a German pharmaceutical company, acquired the testosterone treatment Nebido from Bayer AG for approximately $547.4 million. This strategic move is part of Grünenthal's ongoing acquisition strategy, which includes global rights to Qutenza, rights to ex-Japanese company Zomig, global rights to ex-US company Vimovo, and European rights to Crestor and Nexium. Bayer AG, a German pharmaceutical company specializing in hormone therapy and treatments, was the seller in this acquisition.
Major companies operating in the hormone therapy market include Abbott Laboratories, Bayer AG, Eli Lilly and Company, F. Hoffmann-La Roche, Merck KGaA, Mylan NV, Novartis AG, Novo Nordisk AS, Pfizer Inc., Abbvie Inc., Teva Pharmaceutical Industries Ltd., Perrigo Company Plc., Cipla Inc., Lupin Limited, Sun Pharmaceuticals Industries Ltd., Hikma Pharmaceuticals PLC., Johnsons & Johnsons Services Inc., Boehringer Ingelheim International GmbH, Sanofi S.A., AstraZeneca plc, TherapeuticsMD Inc., Amgen Inc., Genentech Inc., Dr. Reddy's Laboratories Ltd, Allergan PLC, GlaxoSmithKline plc, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Daiichi Sankyo Company Limited.
North America was the largest region in the hormone therapy market in 2024. The regions covered in the hormone therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hormone therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Hormone therapy is a form of treatment aimed at modifying, suppressing, or increasing specific hormones within the body. This therapeutic approach is employed to address hormonal imbalances, such as hypothyroidism and other related conditions.
Key categories of hormone therapy include estrogen hormone replacement, growth hormone replacement, thyroid hormone replacement, and testosterone replacement. Estrogen hormone replacement therapy involves the administration of estrogen to elevate the body's estrogen levels. This treatment is delivered through various routes, including oral and parenteral methods. It finds application in conditions such as menopause, hypothyroidism, and growth hormone deficiency. Distribution channels for hormone therapy encompass hospital pharmacies, retail pharmacies, and online pharmacies.
The hormone therapy market research report is one of a series of new reports that provides hormone therapy market statistics, including hormone therapy industry global market size, regional shares, competitors with a hormone therapy market share, detailed hormone therapy market segments, market trends and opportunities, and any further data you may need to thrive in the hormone therapy industry. This hormone therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The hormone therapy market includes revenues earned by entities by providing hormone therapies such as insulin therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Hormone Therapy Market Characteristics3. Hormone Therapy Market Trends and Strategies4. Hormone Therapy Market - Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market32. Global Hormone Therapy Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the Hormone Therapy Market34. Recent Developments in the Hormone Therapy Market
5. Global Hormone Therapy Growth Analysis and Strategic Analysis Framework
6. Hormone Therapy Market Segmentation
7. Hormone Therapy Market Regional and Country Analysis
8. Asia-Pacific Hormone Therapy Market
9. China Hormone Therapy Market
10. India Hormone Therapy Market
11. Japan Hormone Therapy Market
12. Australia Hormone Therapy Market
13. Indonesia Hormone Therapy Market
14. South Korea Hormone Therapy Market
15. Western Europe Hormone Therapy Market
16. UK Hormone Therapy Market
17. Germany Hormone Therapy Market
18. France Hormone Therapy Market
19. Italy Hormone Therapy Market
20. Spain Hormone Therapy Market
21. Eastern Europe Hormone Therapy Market
22. Russia Hormone Therapy Market
23. North America Hormone Therapy Market
24. USA Hormone Therapy Market
25. Canada Hormone Therapy Market
26. South America Hormone Therapy Market
27. Brazil Hormone Therapy Market
28. Middle East Hormone Therapy Market
29. Africa Hormone Therapy Market
30. Hormone Therapy Market Competitive Landscape and Company Profiles
31. Hormone Therapy Market Other Major and Innovative Companies
35. Hormone Therapy Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Hormone Therapy Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on hormone therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for hormone therapy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The hormone therapy market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- the market characteristics section of the report defines and explains the market.
- the market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- the forecasts are made after considering the major factors currently impacting the market. These include:
- the forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- the regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- the competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- the trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) by Therapy: Estrogen Hormone Replacement; Growth Hormone Replacement; Thyroid Hormone Replacement; Testosterone Replacement2) by Route of Administration: Oral; Parenteral; Other Routes of Administration
3) by Indication: Menopause; Hypothyroidism; Growth Hormone Deficiency; Other Indications
4) by Distribution Channel: Hospitals Pharmacies; Retail Pharmacies and Stores; Online Pharmacies
Subsegments:
1) by Estrogen Hormone Replacement: Systemic Estrogen Therapy; Local Estrogen Therapy; Combination Estrogen-Progestin Therapy2) by Growth Hormone Replacement: Recombinant Growth Hormones; Synthetic Growth Hormones
3) by Thyroid Hormone Replacement: Levothyroxine; Liothyronine; Natural Desiccated Thyroid
4) by Testosterone Replacement: Injectable Testosterone; Transdermal Testosterone; Oral Testosterone; Pellets
Key Companies Mentioned: Abbott Laboratories; Bayer AG; Eli Lilly and Company; F. Hoffmann-La Roche; Merck KGaA
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
Some of the major companies featured in this Hormone Therapy market report include:- Abbott Laboratories
- Bayer AG
- Eli Lilly and Company
- F. Hoffmann-La Roche
- Merck KGaA
- Mylan NV
- Novartis AG
- Novo Nordisk AS
- Pfizer Inc.
- Abbvie Inc.
- Teva Pharmaceutical Industries Ltd.
- Perrigo Company Plc.
- Cipla Inc.
- Lupin Limited
- Sun Pharmaceuticals Industries Ltd.
- Hikma Pharmaceuticals PLC.
- Johnsons & Johnsons Services Inc.
- Boehringer Ingelheim International GmbH
- Sanofi S.A.
- AstraZeneca plc
- TherapeuticsMD Inc.
- Amgen Inc.
- Genentech Inc.
- Dr. Reddy's Laboratories Ltd
- Allergan PLC
- GlaxoSmithKline plc
- Bristol-Myers Squibb Company
- Takeda Pharmaceutical Company Limited
- Astellas Pharma Inc.
- Daiichi Sankyo Company Limited
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | February 2025 |
| Forecast Period | 2025 - 2029 |
| Estimated Market Value ( USD | $ 21.1 Billion |
| Forecasted Market Value ( USD | $ 28.46 Billion |
| Compound Annual Growth Rate | 7.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 31 |
